Unacceptable specimens: Blood/Bone Marrow collected in heparin (green-top) tubes. Test CANNOT be performed on Formalin-Fixed, Paraffin Embedded Tissue
Storage/Transport Temperature
Refrigerated
Performed
M-F Molecular Diagnostics Laboratory
Notes
This assay utilizes clonal amplification by emulsion PCR and Next Generation Sequencing using semiconductor technology. The assay is performed as a modified panel based on the Ion Oncomine Myeloid Sequencing Panel.
The CCAAT/enhancer binding protein, alpha (CEBPA) gene encodes a transcription factor with a leucine zipper motif that binds CCAAT motifs in the promoter regions of target genes. CEBPA mutations are observed in 10-20% of patients diagnosed with AML. CEBPA biallelic mutations (as opposed to monoallelic) are now associated with a favorable prognosis in AML (in the absence of FLT3-ITD) and biallelic mutation is required for recognition as the separate entity under the 2017 World Health Organization (WHO) classification “AML with Biallelic Mutation of CEBPA” (Swerdlow, S. et al 2017, Revised 4th Edition).
The limit of detection for this assay is approximately 5% mutant allele, but may vary depending on the specific mutation.
Performed
M-F Molecular Diagnostics Laboratory
Methodology
Next Generation Sequencing
Reported
Results reported within 7-10 business days
Reference Interval
No Mutations detected
Interpretive Data
Interpretation done by pathologist
CPT Codes
81218
UMR Reference Code: CEBPA82
Test Build Information
OrderCode
OrderName
ResultCode
ResultName
CPT
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
81218
AOE Information (Ask at Order Entry Questions)
Order Code
Order Description
AOE Code
AOE Name
Answer
Answer code
question type
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
Unacceptable specimens: Blood/Bone Marrow collected in heparin (green-top) tubes. Test CANNOT be performed on Formalin-Fixed, Paraffin Embedded Tissue
Storage/Transport Temperature
Refrigerated
Performed
M-F Molecular Diagnostics Laboratory
Notes
This assay utilizes clonal amplification by emulsion PCR and Next Generation Sequencing using semiconductor technology. The assay is performed as a modified panel based on the Ion Oncomine Myeloid Sequencing Panel.
The CCAAT/enhancer binding protein, alpha (CEBPA) gene encodes a transcription factor with a leucine zipper motif that binds CCAAT motifs in the promoter regions of target genes. CEBPA mutations are observed in 10-20% of patients diagnosed with AML. CEBPA biallelic mutations (as opposed to monoallelic) are now associated with a favorable prognosis in AML (in the absence of FLT3-ITD) and biallelic mutation is required for recognition as the separate entity under the 2017 World Health Organization (WHO) classification “AML with Biallelic Mutation of CEBPA” (Swerdlow, S. et al 2017, Revised 4th Edition).
The limit of detection for this assay is approximately 5% mutant allele, but may vary depending on the specific mutation.
Ordering
Performed
M-F Molecular Diagnostics Laboratory
Methodology
Next Generation Sequencing
Reported
Results reported within 7-10 business days
Result Interpretation
Reference Interval
No Mutations detected
Interpretive Data
Interpretation done by pathologist
Administrative
CPT Codes
81218
UMR Reference Code: CEBPA82
RPS Interface Information
Test Build Information
OrderCode
OrderName
ResultCode
ResultName
CPT
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
81218
AOE Information (Ask at Order Entry Questions)
Order Code
Order Description
AOE Code
AOE Name
Answer
Answer code
question type
CEBPA
CEBPA Mutation Analysis by Next Generation Sequencing
